Natixis Advisors L.P. Sells 4,252 Shares of Quest Diagnostics Inc (DGX)

Natixis Advisors L.P. decreased its holdings in Quest Diagnostics Inc (NYSE:DGX) by 10.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,760 shares of the medical research company’s stock after selling 4,252 shares during the period. Natixis Advisors L.P.’s holdings in Quest Diagnostics were worth $3,788,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of DGX. Wagner Wealth Management LLC bought a new position in Quest Diagnostics in the fourth quarter worth approximately $106,000. Fuller & Thaler Asset Management Inc. bought a new position in Quest Diagnostics in the fourth quarter worth approximately $118,000. Optimum Investment Advisors bought a new position in Quest Diagnostics in the first quarter worth approximately $130,000. Assetmark Inc. raised its stake in Quest Diagnostics by 139.5% in the fourth quarter. Assetmark Inc. now owns 1,473 shares of the medical research company’s stock worth $145,000 after buying an additional 858 shares in the last quarter. Finally, Icon Wealth Partners LLC acquired a new position in shares of Quest Diagnostics during the fourth quarter worth $147,000. 88.31% of the stock is owned by institutional investors.

Get Quest Diagnostics alerts:

In other Quest Diagnostics news, Chairman Stephen H. Rusckowski sold 168,490 shares of the company’s stock in a transaction on Friday, May 25th. The shares were sold at an average price of $107.00, for a total value of $18,028,430.00. Following the sale, the chairman now directly owns 359,559 shares of the company’s stock, valued at $38,472,813. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey M. Leiden sold 1,644 shares of the company’s stock in a transaction on Tuesday, May 29th. The shares were sold at an average price of $105.61, for a total transaction of $173,622.84. Following the completion of the sale, the director now directly owns 6,000 shares in the company, valued at $633,660. The disclosure for this sale can be found here. Over the last three months, insiders sold 315,336 shares of company stock worth $33,425,016. 1.79% of the stock is owned by insiders.

NYSE DGX opened at $107.95 on Monday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.14 and a current ratio of 1.23. Quest Diagnostics Inc has a 1 year low of $90.10 and a 1 year high of $112.96. The firm has a market capitalization of $14.66 billion, a P/E ratio of 19.99, a PEG ratio of 2.13 and a beta of 0.70.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, April 19th. The medical research company reported $1.52 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.52. Quest Diagnostics had a return on equity of 15.44% and a net margin of 10.19%. The firm had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same period in the prior year, the firm earned $1.33 EPS. The firm’s revenue was up 3.7% on a year-over-year basis. analysts expect that Quest Diagnostics Inc will post 6.61 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, July 23rd. Investors of record on Monday, July 9th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.85%. The ex-dividend date is Friday, July 6th. Quest Diagnostics’s payout ratio is 37.04%.

A number of equities analysts have recently issued reports on DGX shares. Mizuho reaffirmed a “buy” rating on shares of Quest Diagnostics in a research report on Friday, May 25th. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a research report on Tuesday, May 22nd. Argus raised Quest Diagnostics from a “hold” rating to a “buy” rating and upped their price target for the stock from $104.14 to $116.00 in a research report on Wednesday, March 7th. Canaccord Genuity upped their price target on Quest Diagnostics from $113.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, March 19th. Finally, Morgan Stanley raised Quest Diagnostics from an “underweight” rating to an “equal weight” rating and set a $103.00 price target on the stock in a research report on Wednesday, March 14th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $110.72.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Leave a Reply

Your email address will not be published. Required fields are marked *